This article was originally published in Start Up
Executive SummarySome ethicists and policy experts continue expressing concern about deCode genetics' plans to analyze the medical records and DNA of as many Icelanders as possible. Critics say the firm should ask permission of every person whose records it wishes to analyze; deCode says "presumed consent" is standard in medical research. Investors, apparently, aren't bothered. deCode went public in mid-July and is now trading at a valuation of $1.08 billion.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.